Senzime Unveils the Next Set of Innovations in Neuromuscular Monitoring With the Launch of EMGINE Sirius

About this update from Senzime Ab

[{"type":"text","content":"UPPSALA, SE / ACCESS Newswire / December 10, 2025 / Senzime (STO:SEZI)(OTCQX:SNZZF) - Senzime AB (publ) today announced the launch of the latest series of innovative features for its next-generation TetraGraph® system. The new EMGINETM Sirius software suite will be showcased at the 79th PostGraduate Assembly in Anesthesiology (PGA) conference, taking place December 12-15 in New York City, NY, USA.","length":400,"tagName":"p"},{"type":"text","content":"EMGINE is a proprietary software suite for the next-generation TetraGraph platform. The new EMGINE Sirius release is the result of continuous innovation grounded in billions of real-world patient data points, recently published research, and collaborations with clinicians worldwide. Key new features include:","length":309,"tagName":"p"},{"type":"text","content":"1. TetraGraph Intubation Readiness Indicator In alignment with the latest intubation guidelines, TetraGraph now provides a patent-pending parameter indicating when a patient's vocal cords are fully relaxed by anesthetic drugs-supporting safer, smoother, and more predictable intubation conditions.","length":302,"tagName":"p"},{"type":"text","content":"2. Personalized neuromuscular monitoringUnique algorithms that individualize monitoring based on each patient's anatomy for unmatched clinical accuracy and safety. This allows clinicians to begin monitoring either before or after neuromuscular blocking agents have been administered.","length":288,"tagName":"p"},{"type":"text","content":"3. Adaptive, high-current stimulation capabilities Configurable stimulation levels up to 80 mA enabling monitoring of the most challenging patients.","length":149,"tagName":"p"},{"type":"text","content":""Personalizing anesthesia is an artform, and Senzime continues to deliver science-based innovations that empower clinicians to make the right interventions-driving safer care and reducing costs. The EMGINE Sirius software suite unveils the next set of breakthrough features in neuromuscular monitoring. TetraGraph users benefit not only from the industry's broadest range of disposable sensors, but also from an integrated monitoring platform that is continuously updated with new capabilities to elevate clinical outcomes", said Philip Siberg, CEO of Senzime.","length":574,"tagName":"p"},{"type":"text","content":""A recent ...

More updates from Senzime Ab